Suppr超能文献

亮抑蛋白酶肽、莫能菌素和秋水仙碱对分离的大鼠肝细胞中两条去唾液酸糖蛋白受体途径介导的配体降解的不同作用。

Differential effects of leupeptin, monensin and colchicine on ligand degradation mediated by the two asialoglycoprotein receptor pathways in isolated rat hepatocytes.

作者信息

Clarke B L, Weigel P H

机构信息

Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550.

出版信息

Biochem J. 1989 Aug 15;262(1):277-84. doi: 10.1042/bj2620277.

Abstract

We have shown that degradation of asialo-orosomucoid (ASOR) in isolated rat hepatocytes occurs by two different intracellular pathways [Clarke, Oka & Weigel (1987) J. Biol. Chem. 262, 17384-17392] mediated by two subpopulations of cell surface galactosyl (Gal) receptors, designated State 1 or State 2 receptors. In the present study, several inhibitors were tested for their effects on ligand degradation by the State 1 or State 2 pathway. Leupeptin, monensin and chloroquine completely inhibited degradation of 125I-labelled ASOR in both pathways. Dose-response studies showed, however, that the State 2 pathway was more sensitive to leupeptin or monensin than the State 1 pathway. No differences were observed with chloroquine. For example, the onset of inhibition in the State 2 and State 1 pathways occurred at about 0.05 and 0.3 microM-leupeptin respectively, a 6-fold difference. At 3.5 microM-monensin, 125I-ASOR degradation in the State 2 pathway was completely blocked, whereas degradation in the State 1 pathway was essentially unaffected. Colchicine was observed to give the largest differential sensitivity between the two pathways. The State 2 degradation pathway was about 30-fold more sensitive to colchicine than the State 1 pathway. Lumicolchicine had no affect. The onset of inhibition of the rate of 125I-ASOR degradation in the State 2 and State 1 pathways occurred at approximately 0.1 and 3.0 microM-colchicine respectively. At very high concentrations (greater than 0.1 mM), the State 1 pathway could be completely inhibited. We conclude that intracellular 125I-ASOR processing or delivery to degradative compartments in both the State 1 and State 2 Gal receptor pathways requires low pH. Ligand delivery to the degradative compartment does not require microtubules in the State 1 pathway, consistent with the very rapid onset of degradation in this pathway. The State 2 degradation pathway does require microtubules.

摘要

我们已经表明,去唾液酸血清类黏蛋白(ASOR)在分离的大鼠肝细胞中的降解通过两种不同的细胞内途径发生[克拉克、冈和韦格尔(1987年)《生物化学杂志》262卷,17384 - 17392页],这两种途径由细胞表面半乳糖基(Gal)受体的两个亚群介导,分别称为1型或2型受体。在本研究中,测试了几种抑制剂对1型或2型途径配体降解的影响。亮抑酶肽、莫能菌素和氯喹完全抑制了两种途径中125I标记的ASOR的降解。然而,剂量反应研究表明,2型途径比1型途径对亮抑酶肽或莫能菌素更敏感。氯喹未观察到差异。例如,2型和1型途径中抑制的起始浓度分别约为0.05和0.3微摩尔亮抑酶肽,相差6倍。在3.5微摩尔莫能菌素时,2型途径中125I - ASOR的降解被完全阻断,而1型途径中的降解基本不受影响。观察到秋水仙碱在两种途径之间产生的差异敏感性最大。2型降解途径对秋水仙碱的敏感性比1型途径高约30倍。光秋水仙碱没有影响。2型和1型途径中125I - ASOR降解速率抑制的起始浓度分别约为0.1和3.0微摩尔秋水仙碱。在非常高的浓度(大于0.1毫摩尔)时,1型途径可被完全抑制。我们得出结论,在1型和2型Gal受体途径中,细胞内125I - ASOR的加工或转运至降解区室都需要低pH值。配体转运至降解区室在1型途径中不需要微管,这与该途径中降解的快速起始一致。2型降解途径确实需要微管。

相似文献

引用本文的文献

本文引用的文献

7
The hepatic asialoglycoprotein receptor.肝去唾液酸糖蛋白受体
CRC Crit Rev Biochem. 1984;16(3):207-33. doi: 10.3109/10409238409108716.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验